Abstract:Background: Primary triple-negative breast cancer (TNBC) is influenced by hypoxic microenvironments that promote metastasis and paclitaxel (PTX) resistance. However, few studies have attempted to understand how hypoxia promotes metastasis and drug resistance and provide a solution to these problems, especially in TNBC. Methods: Transcriptome sequencing of TNBC cells under hypoxic conditions was performed to identify C1QBP. The mechanism of HIF-1α induced C1QBP under both hypoxia and normoxia were investigated by ChIP-qPCR. Next the role of C1QBP in mediating metastasis and chemoresistance to PTX and regulating VCAM-1 were studied by in vitro and in vivo experiments. Then the anti-cancer effect of C1QBP inhibition in hypoxic environment was investigated. Furthermore, TCGA database and clinical tissue microarrays in our cohort were used to verify the correlation of C1QBP with the expression of HIF-1α, VCAM-1, and p65. Results: Here, we report that hypoxia-induced HIF-1α upregulated the expression of C1QBP; the inhibition of C1QBP notably blocked metastasis of TNBC cells and increased their sensitivity to PTX under hypoxic conditions in vitro and in vivo. Depletion of C1QBP decreased VCAM-1 expression by reducing p65 protein levels in the nucleus and, remarkably, suppressed the activation of hypoxia-induced PKC–NF-κβ signaling. Moreover, tissue microarray and immunohistochemical staining showed a positive correlation between the protein levels of C1QBP and that of p65 and VCAM-1 in breast cancer patients (especially TNBC). The analysis from TCGA database further confirmed the correlation between the mRNA levels of C1QBP, HIF-1α, and VCAM-1 in TNBC patients. Conclusions: Hypoxia-induced HIF-1α upregulates C1QBP expression of TNBC cells. Deregulated C1QBP may inhibit hypoxia-induced metastasis and PTX resistance along with reducing the activation of the PKC–NF-κβ–VCAM-1 axis. Targeting C1QBP in the presence of PTX may be a potential therapeutic against hypoxia-induced metastatic or drug resistant TNBC. Funding Statement: Haiyan Fund Project of Harbin Medical University Cancer Hospital (Grant number: JJQN 2018-06); Health Committee Fund Project of Heilongjiang Province (Grant number: 2019-056); National Natural Science Foundation of China, Grant/Award Numbers: 81972706; National Natural Science Foundation of China, Grant/Award Numbers: 81602639; National Natural Science Foundation of China, Grant/Award Numbers: 81602323; National Natural Science Foundation of China, Grant/Award Numbers: 81872149; Heilongjiang postdoctoral fundation (LBH-Z18222). Outstanding Youth Project of Heilongjiang Provincial Natural Science Foundation, Grant/Award Number: YQ2019H027; 9. Wu Lien‐ the Science Foundation of Harbin Medical University, Grant/Award Number: WLD‐ QN1706; Young Elite Training Foundation Grant of Harbin Medical University Cancer Hospital, Grant/Award Number: JY2016‐ 02; Distinguished Young Scholars of Harbin Medical University Cancer Hospital, Grant/Award Number: JCQN2018‐ 03.Declaration of Interests: The authors declare no conflict of interest. Ethics Approval Statement: The Medical Ethics Committee approved this study and all the relevant information was provided to the patients who were willing to participate in the study.

C1QBP regulates mitochondrial plasticity to impact tumor progression and antitumor immune response

Mitochondrial C1QBP is essential for T cell antitumor function by maintaining mitochondrial plasticity and metabolic fitness

Complement C1q binding protein regulates T cells' mitochondrial fitness to affect their survival, proliferation, and anti-tumor immune function

Research Progress on Mitochondria Regulating Tumor Immunity.

The Mitochondrial Protein C1QBP Promotes Hepatocellular Carcinoma Progression by Enhancing Cell Survival, Migration and Invasion

Interactome Analysis Reveals that C1QBP (complement component 1, q subcomponent binding protein) Is Associated with Cancer Cell Chemotaxis and Metastasis

CtBP maintains cancer cell growth and metabolic homeostasis via regulating SIRT4

Mitochondria-Shaping Proteins and Chemotherapy

C1QBP Mediates Breast Cancer Cell Proliferation and Growth via Multiple Potential Signalling Pathways

Hypoxia-Mediated Complement 1q Binding Protein Regulates Metastasis and Chemoresistance in Triple-Negative Breast Cancer and Modulates the PKC-NF-κB-VCAM-1 Signaling Pathway

SSBP1 Upregulation in Colorectal Cancer Regulates Mitochondrial Mass

Mitochondrial Immune Regulation and Anti-Tumor Immunotherapy Strategies Targeting Mitochondria

Complement Component 1, Q Subcomponent Binding Protein (C1QBP) in Lipid Rafts Mediates Hepatic Metastasis of Pancreatic Cancer by Regulating IGF‐1/IGF‐1R Signaling

C1q + tumor-associated macrophages contribute to immunosuppression through fatty acid metabolic reprogramming in malignant pleural effusion

Immunological and Prognostic Roles of Complement C1q binding protein in Breast Cancer

Hypoxia-Mediated C1QBP Regulates Metastasis and Chemoresistance in Triple-Negative Breast Cancer and Modulates VCAM-1 Expression Via Canonical Nf-Κβ Signaling

Systematic Multiomics Analysis of Alterations in C1QBP mRNA Expression and Relevance for Clinical Outcomes in Cancers

Mitochondrial C1qbp promotes differentiation of effector CD8 + T cells via metabolic-epigenetic reprogramming

Mitochondrial Dynamics Controls Anti-Tumour Innate Immunity by Regulating CHIP-IRF1 Axis Stability

Mitochondrial Regulation of Tumor-associated Macrophages

Regulation of CD8+ T cells by lipid metabolism in cancer progression